Company Overview and News
KUALA LUMPUR (Oct 15): The FBM KLCI rose 0.24% at mid-morning today, defending its level above the 1,730-point level, lifted by gains at select blue chips.
HLFBF 7293 BRDBF MLYNF 7113 TPGVF 2089 5199 5210 3026 2836 HIPEF GEBHF HRGHY 5183 MLYBY PECGF UPBMF 1082 5681 5168 TGLVY 5436 5238 1155 0047
KUALA LUMPUR (Oct 9): Yinson Holdings Bhd said today its indirect wholly-owned subsidiary Knock Allan Pte Ltd had yesterday received a termination notice for a floating production storage and offloading (FPSO) facility contract from CNR International (Olowi) Ltd "on the ground of convenience".
7293 BSMAF 1818
Kenanga Research added that green field-based projects, such as exploration or new-oil production based jobs, could see a lagged surge, given its huge capex nature and drawn-out planning process. The research house said the companies likely to benefit from this would be those with direct exploration and production (E&P) exposure such as Sapura Energy Bhd, Reach Energy Bhd and Hibiscus Petroleum Bhd.
7293 5141 HIPEF 5256 5199
KUALA LUMPUR (Oct 1): The FBM KLCI closed down 0.69 point or 0.04% after volatile trade while Bursa Malaysia's energy index rose 46.79 points or 4.16% as Brent crude oil prices climbed to a four-year high at above US$80 a barrel.
7293 1201 5681 BSMAF 5256 1818
KUALA LUMPUR: JF Apex Research expects CIMB Group Holdings Bhd , Bintai Kinden Corp Bhd, Mynews Holdings Bhd, Yinson Holdings Bhd and Sapura Energy Bhd to be among the stocks to watch today.
7293 1023 5347 TNABY TNABF CIMDF
KUALA LUMPUR (Sept 25): CIMB IB Research has maintained “Hold” on Yinson Holdings Bhd at RM4.55 with a higher target price of RM4.72 (from RM4.70) and said Yinson’s 1HFY1/19 core net profit, at 43% of house previous forecast, was in line given that a stronger US$ will help boost its future ringgit earnings.
KUALA LUMPUR (Sept 24): Based on corporate announcements and news flow today, companies in focus tomorrow (Tuesday, Sept 25) may include: CIMB, Bina Puri, Heng Huat, Bintai Kinden, Mynews, MLabs, Yinson, Berjaya Media and Parkson Holdings.
PKSGF 7293 6025 3368 0175 CIMDF 5932 5657 1023 5347 PKSGY TNABY TNABF
KUALA LUMPUR (Sept 24): Yinson Holdings Bhd’s net profit declined nearly 12% to RM73.67 million for the second financial quarter ended July 31 (2QFY19) from RM83.6 million a year ago.
7293 SSUMF BSMAF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...